July 2023
Tebubio, a European leader in France
Established in 1953 and still a family run business to this day, Tebubio facilitates Life Sciences research in France and throughout Europe. With over 80 team members across Europe, we provide researchers with a range of innovative solutions in many cutting edge areas, such as gene and cell therapy, and drug discovery, as well as towards developing treatments based on messenger RNA (mRNA). Tebubio is committed to continuously innovating and better accompanying French and European researchers with their projects.
70 years...and still innovating!
Our pan-European presence through our network of 9 local offices, enables us to be close to researchers and accompany them by offering a holistic range of solutions:
- Fast and simplified acess to a large selection of products and reagents, from over 180 specialised manufacturers worldwide
- Technical expertise and personalised solutions, with services performed at our biotechnological laboratory based in France
- Logistical and financal expertise for customised procurement solutions, in full respect of ethical, ecological and legal regulations to alleviate administrative constraints for researchers
Tebubio was at the time one of the earliest companies to provide frozen cells and recombinant cytokines, and has long been actively contributing towards developing physiologically relevant in vitro human research models, thus reducing the need for animals throughout the early stages of testing.
Since the beginning of the 21st century, Tebubio has been an actively present in the area of messenger RNA and has accompanied companies such as BioNTech, Moderna and CureVac in their research on new therapeutical treatments.
Right from the early months of the COVID-19 pandemic, we were thus able to provide European researchers with the tools necessary for the development of mRNA based treatments, offering them access to our partner TriLink BioTechnologies’ solutions (notably used in the Pfizer-BioNTech vaccine), but also with our strong expertise in designing customised mRNA.
The RNAvenir project: Producing mRNA in France
Throughout 2022, in anticipation of and in response to increasing needs of European researchers, at Tebubio we developed our own research grade mRNA production service. In a highly competitive global context, researchers need to be able to quickly access small quantities of customised mRNA, in order to rapidly validate new Proofs of Concept (POC) in relation to mRNA treatments.
With over 150 projects already performed for both private and academic customers (AstraZeneca, Merck, Novartis, Innate Pharma, King’s College London, Institut Curie, etc.), and through collaborations such as with the University of Oxford, Tebubio offers an ever growing offer in answer to a variety of challenges, such as packaging and delivery of mRNA molecules, but also efficacy and toxicity testing on a variety of cellular models.
Tebubio’s RNAvenir project aims to expand and strengthen our services, to further facilitate French and European research.
Tebubio's platform for therapeutic mRNA RNAvenir
From RNA production (in orange), delivery into cells (in blue) through encapsulation (in purple)
Tebubio in a few figures
- 25M turnover
- 9 local offices in Europe
- +112% growth since 2019
- 80% of turnover is export
- 80+ collaborators of which + 1/4 are PhDs
- 750m² dedicated laboratory area
- 150 mRNA projects performed since 2022